Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab and M1774 in ARID1A-mutated Recurrent Endometrial Cancer
NCT06518564Phase 2Active, not recruiting
- Start
- Nov 2024
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tuvusertib in endometrial cancer (EC). Started Nov 2024; status: active, not recruiting.
02
Drugs
tuvusertib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06518564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06518564.